Last reviewed · How we verify
Radicava ORS
Radicava ORS is an oral formulation of edaravone that acts as a free radical scavenger to reduce oxidative stress in motor neurons.
Radicava ORS is an oral formulation of edaravone that acts as a free radical scavenger to reduce oxidative stress in motor neurons. Used for Amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | Radicava ORS |
|---|---|
| Also known as | Edaravone ORS |
| Sponsor | Shanghai Auzone Biological Technology Co., Ltd. |
| Drug class | Free radical scavenger; antioxidant |
| Target | Free radicals (hydroxyl radicals); non-selective antioxidant mechanism |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Edaravone is a small-molecule antioxidant that crosses the blood-brain barrier and selectively scavenges free radicals, particularly hydroxyl radicals, which are implicated in neuronal damage in amyotrophic lateral sclerosis (ALS). By reducing oxidative stress and neuroinflammation, it may slow the rate of motor neuron degeneration. The ORS (oral suspension) formulation provides an oral alternative to the intravenous edaravone (Radicava IV).
Approved indications
- Amyotrophic lateral sclerosis (ALS)
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Headache
Key clinical trials
- Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects (PHASE1)
- Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |